Association Between Cannabis Use and Healthcare Utilization in Patients With Irritable Bowel Syndrome: A Retrospective Cohort Study

IntroductionIrritable bowel syndrome (IBS) is a frequent cause of abdominal pain and altered bowel habits, which is associated with significant healthcare utilization. The effects of the active compound of cannabis, Δ9-tetrahydrocannabinol (THC), on gut motility and tone have been studied in several...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2020-05, Vol.12 (5), p.e8008-e8008
Main Authors: Desai, Parth, Mbachi, Chimezie, Vohra, Ishaan, Salazar, Miguel, Mathew, Madhu, Randhawa, Tejinder, Haque, Zohaib, Wang, Yuchen, Attar, Bashar, Paintsil, Isaac
Format: Article
Language:English
Subjects:
Abdomen
Ambulatory care
Anemia
Clinical outcomes
Cohort analysis
Constipation
Diabetes
Endoscopy
Family income
Gastroenterology
Health care policy
Health services utilization
Heart failure
Hospitals
Hypothyroidism
Inflammatory bowel disease
Internal Medicine
Irritable bowel syndrome
Marijuana
Medicaid
Morbidity
Motility
Pain
Quality of life
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionIrritable bowel syndrome (IBS) is a frequent cause of abdominal pain and altered bowel habits, which is associated with significant healthcare utilization. The effects of the active compound of cannabis, Δ9-tetrahydrocannabinol (THC), on gut motility and tone have been studied in several experimental models. It is unknown whether these effects correlate with improved healthcare utilization among cannabis users. The purpose of this study is to evaluate the impact of cannabis use on inpatient length of stay and resource utilization for patients with a primary discharge diagnosis of IBS.MethodsData were extracted from the Healthcare Cost and Utilization Project Nationwide Inpatient Sample database from 2010 to 2014 for all patients with a primary discharge diagnosis of IBS. Cannabis users (n=246) and non-users (n=9147) were directly compared for various clinical outcomes.ResultsCannabis users were less likely to have the following: upper gastrointestinal endoscopy (17.9% vs. 26.1%; adjusted odds ratio [aOR]: 0.51 [0.36 to 0.73]; p
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.8008